Pages

▼
Showing posts with label Medicare Part D. Show all posts
Showing posts with label Medicare Part D. Show all posts
Thursday, October 08, 2026

The IRA Fixed One Medicare Part D Distortion—But Patients Now Face New Tradeoffs (rerun)

›
This week, we're rerunning some popular posts while we put the finishing touches on DCI’s 2026-27 Economic Report on Pharmaceutical Whol...
Tuesday, September 29, 2026

Drug Channels News Roundup, September 2026: The 340B Margin Squeeze, Economics of Cutting List Price, Patient Adherence from Copay Cards, Negative Part D Premiums, and Drug Channel Dating Profiles

›
By Bryce Platt, PharmD Football season is officially back. Personally, my signal is hearing my uncle curse about bad calls from 1,000 mil...
Tuesday, September 01, 2026

The Private Label Biosimilar Paradox in Medicare Part D

›
By Tyler Novotny and Bryce Platt PBM-affiliated private label biosimilars would seem to have a built-in formulary advantage. But for us...
Tuesday, August 25, 2026

Drug Channels News Roundup, August 2026: 340B Rebate Model v2, Patients Feeling Drug Costs, Specialty Drug Spending Drivers, Impact on Coverage from the IRA, and a Drug Price Adventure

›
By Bryce Platt, PharmD Kids are heading back to school, but the drug channel never stops handing out homework. Fortunately, we did some of...
Tuesday, August 11, 2026

The K-Shaped Pharmacy Shakeout: Consolidation in Cities, Lost Access in Rural America

›
By Bryce Platt, PharmD The United States has almost 8,000 fewer retail pharmacies than it did in 2018, and more than 2,000 closed in 2025 ...
Tuesday, August 04, 2026

Who Will Pay for Prescription Drugs in 2034? Medicare's Surprising Rise in the Latest Government Forecasts

›
By Adam J. Fein, Ph.D. and Greis Kapexhiu In late June, the boffins at the Centers for Medicare & Medicaid Services (CMS) released the...
Tuesday, July 28, 2026

Drug Channels News Roundup, July 2026: Biosimilar Launch Strategy, Part D Spending Trends, Rural 340B Hospitals, What Employers Can Do About 340B, and Drug Channel Villains

›
By Bryce Platt, PharmD Summer's in full swing, but the drug channel didn't take a break. What better way to spend the summer than...
Tuesday, June 16, 2026

The IRA Fixed One Medicare Part D Distortion—But Patients Now Face New Tradeoffs

›
By Bryce Platt, PharmD For years, Medicare Part D plans often preferred high-list/high-rebate branded multiple sclerosis (MS) drugs over l...
Tuesday, April 28, 2026

Drug Channels News Roundup, April 2026: PBM Specialty Pharmacy Steering, MLR Profit Shifting, Hospitals’ Fake Prices, and a Peek Behind the Scenes at DCI

›
By Adam J. Fein, Ph.D. Spring has officially arrived at Drug Channels' worldwide headquarters in beautiful downtown Philadelphia. (Photo...
Wednesday, April 08, 2026

List Price Reductions Will Deflate the Gross-to-Net Bubble–and Threaten Pharmacy and 340B Profits from IRA-Negotiated Drugs (rerun)

›
This week, I’m rerunning some popular posts while we prepare for Friday’s live video webinar: PBM Industry Update 2026: Trends, Challenges, ...
Tuesday, March 03, 2026

Preorder Now: DCI’s 2026 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers

›
On March 24, 2026, Drug Channels Institute will release The 2026 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers . This re...
Wednesday, February 18, 2026

Medicare Part D Pharmacy Networks in 2026: Supermarkets Dominate as Drugstores Stall and Independents Walk Away

›
By Adam J. Fein, Ph.D. The Centers for Medicare & Medicaid Services (CMS) has just released its initial 2026 data on enrollment in Medic...
Tuesday, February 03, 2026

Latest CMS Data Reveal Six Trends Reshaping U.S. Drug Spending

›
By Adam J. Fein, Ph.D. The boffins at the Centers for Medicare & Medicaid Services (CMS) recently dropped the latest National Health Exp...
Tuesday, December 16, 2025

340B Hit $81 Billion in 2024: Why CMS and the IRA Are Poised to Cool the Program’s Runaway Growth (VIDEO)

›
Yesterday, I published 340B Hit $81 Billion in 2024 (+23%): Why CMS and the IRA Are Poised to Cool the Program’s Runaway Growth . For those ...
Monday, December 15, 2025

340B Hit $81 Billion in 2024 (+23%): Why CMS and the IRA Are Poised to Cool the Program’s Runaway Growth

›
By Adam J. Fein, Ph.D. Whoa. The 340B Drug Pricing Program has once again given new meaning to the word “skyrocketing.” For 2024, discount...
Wednesday, December 10, 2025

Who Will Pay for Prescription Drugs in 2033: DCI’s Takeaways from the Latest Government Forecasts (rerun)

›
This week, I’m rerunning some popular posts while I prepare for Friday's live video webinar: Drug Channels Outlook 2026 . Click here t...
Tuesday, December 02, 2025

List Price Reductions Will Deflate the Gross-to-Net Bubble–and Threaten Pharmacy and 340B Profits from IRA-Negotiated Drugs

›
By Adam J. Fein, Ph.D. Contrary to popular belief, the Inflation Reduction Act’s (IRA) maximum fair prices (MFPs) could temporarily boost p...
Thursday, November 13, 2025

Medicare Part D 2026: Preferred Networks Vanish as the PDP Market Collapses

›
By Adam J. Fein, Ph.D. As I’ve been warning for years, the Inflation Reduction Act of 2022 (IRA) has nearly obliterated the stand-alone Med...
Tuesday, October 28, 2025

Drug Channels News Roundup, October 2025: Vertical Integration Woes, AFPs Gone Wild, Part D’s Decline, 340Bloat, and Dr. G’s ACIP Haunting

›
By Adam J. Fein, Ph.D. Eeek! It’s time for the Drug Channel s Halloween roundup of terrifying tales from the dark corners of the healthcare...
Tuesday, September 30, 2025

Drug Channels News Roundup, September 2025: Mark Cuban Wins (Again), Biosimilar Pricing Double Standards, Part D Collapse, Fresh 340B Facts, and The Pitt

›
By Adam J. Fein, Ph.D. Autumn is here! Curl up with your Labubu’s favorite pumpkin-spiced blog and savor these stories harvested from the g...